Engflag

Fudic-BNF

Quick links to important sections

Fudic-BNF

Fudic-BNF_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fudic-BNF

Quick Facts

Property Description
Active Ingredients Fusidic Acid (Antibiotic) and Beclometasone Dipropionate (Corticosteroid)
Form Topical (Cream or Ointment)
Pharmacological Class Steroid-Antibiotic Combination
Common Use Principle Managing inflammatory skin conditions with suspected or confirmed bacterial involvement
Origin Synthetic (Derived/Modified Chemical Entities)

What Type of Medicine is Fudic-BNF?

Fudic-BNF is classified as a fixed-dose combination product and a Steroid-Antibiotic Combination, designed exclusively for topical dermal application. This preparation delivers the anti-inflammatory and antibacterial components within a single, consistent formulation, making it a specialized dermatologic drug. The utility of such fixed-dose combinations in dermatology is clinically recognized for simplifying treatment when both inflammation and infection coexist. It is commonly supplied as a topical cream or ointment, intended for external use only.

Composition: Beclometasone Dipropionate and Fusidic Acid

The product’s efficacy is based on the combination of the potent corticosteroid Beclometasone Dipropionate and the antibiotic Fusidic Acid. Beclometasone Dipropionate is a synthetic glucocorticoid derivative, classified among the potent Topical Corticosteroids. Fusidic Acid belongs to the unique fusidane class of antibiotics and acts as a bacteriostatic agent. The components are combined to ensure the simultaneous delivery of both a potent anti-inflammatory agent and an antibacterial agent directly to the affected skin area.

What is the General Purpose of This Dual-Action Topical?

The general purpose of this dual-action topical is to manage inflammatory skin conditions that are complicated by or at high risk of developing a bacterial infection. This strategy leverages the dual mechanism: the anti-inflammatory effect of the corticosteroid reduces key symptoms like swelling, redness, and itching, while the antibacterial action controls the growth of susceptible microorganisms. This comprehensive approach is intended to provide a more efficient treatment strategy for addressing both the inflammatory response and potential microbial involvement concurrently.

Regulatory References

  1. Beclometasone Dipropionate

What side effects are possible with Fudic-BNF?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety restrictions for Fudic-BNF (Fusidic Acid/Betamethasone Valerate) as documented in government regulatory sources.

Frequency-Classified Adverse Reactions

The most commonly reported side effects relate to the application site or allergic responses:

Frequency Examples of Reported Effects
Uncommon (ge 1/1,000 to < 1/100) Hypersensitivity, contact dermatitis, skin burning sensation, itching (pruritus), dry skin, application site pain or irritation.
Rare (ge 1/10,000 to < 1/1,000) Redness (erythema), hives (urticaria), rash, application site swelling or vesicles.
Not Known Blurred vision, withdrawal reactions (rebound flares) after stopping long-term use.

Serious and Systemic Safety Concerns

The primary serious concerns are associated with the absorption of the corticosteroid component, Betamethasone Valerate, particularly when used extensively or for long periods. These effects may involve system-organ classes beyond the skin:

  • Hormonal Effects: Adrenal suppression (HPA-axis suppression) and Cushing’s syndrome, which may occur due to significant systemic absorption.
  • Ocular Effects: Glaucoma, cataract, or increased pressure inside the eye (intra-ocular pressure) if the medicine is used near the eyes or over long durations.
  • Local Corticosteroid Effects: Skin thinning (atrophy), stretch marks (striae), and blood vessel dilation (telangiectasia) are recognized risks with prolonged topical steroid use.

Safety Restrictions and Limitations

The medicine is subject to regulatory restrictions:

  • Contraindications: Must not be used if there is a known allergy to any component, or in the presence of viral skin infections (e.g., herpes, chickenpox), fungal infections, tuberculosis-related skin conditions, rosacea, or perioral dermatitis.
  • Application Cautions: Use near the eyes should be strictly avoided. Use on the face should be limited. Prolonged or widespread use, especially under airtight dressings (occlusion), increases the risk of systemic side effects.
  • Population Specific: Children are at a greater risk of systemic side effects, such as adrenal suppression, due to their higher skin surface-to-body weight ratio.
  • Fire Hazard: Regulatory documents warn that fabric which has been in contact with the product burns more easily and is a serious fire hazard.

Overdose and Emergency Response

Overdose and When to Seek Help

For a topical medication like Fudic-BNF (a combination of fusidic acid and a corticosteroid), an overdose from typical external use is considered unlikely to cause severe systemic symptoms. The medication is formulated for application to the skin, and the amount absorbed into the bloodstream is usually minimal.

Documented Overdose Scenarios

The primary risks associated with an overdose situation are related to prolonged or widespread application, or accidental ingestion:

  • Excessive Topical Use: Applying the product in large volumes for a prolonged period may lead to local side effects, such as skin irritation, or, rarely, signs of excessive corticosteroid absorption (e.g., thinning skin).
  • Accidental Ingestion: Swallowing the medicine is a scenario where immediate medical intervention may be required. Though the amount of active ingredients may be relatively low, regulatory information specifies that accidental ingestion may cause harm.

Emergency Actions and Required Medical Attention

  • If you have applied too much of the cream, the official instruction is to simply wipe out the excess of the medicine with tissue or cotton.
  • If the medicine is accidentally swallowed, you must contact your doctor immediately or visit the nearest hospital. This situation warrants urgent medical attention, even if there are no immediate signs of discomfort, as the label specifies the potential for harm.

Overdose classification is constrained by the application route; while a topical overdose is generally minor and managed procedurally, accidental oral intake is explicitly defined as a scenario requiring immediate professional medical help.

Therapeutic Uses of Fudic-BNF

What Fudic-BNF Treats: Main Uses and Benefits

Fudic-BNF is commonly used to help with skin conditions where both inflammation and bacterial infection are present, and is considered relevant within the management of skin disorders. This combination supports relief from the overall symptom load, addressing two major components of skin distress concurrently.

The preparation is primarily applied for eczematous dermatoses, including atopic, discoid, and seborrhoeic eczema, as well as other forms of dermatitis when secondary bacterial infection is confirmed or suspected. It is relevant in contexts where short-term symptomatic assistance is needed for pronounced manifestations like redness, swelling, itching, crusting, and purulent discharge.

The therapeutic approach of this combination is relevant: “It is applied in clinical settings that involve acute or unstable symptom patterns where relief from both infection signs and inflammation is necessary.” By supporting the clearance of microbial signs and moderating inflammatory symptoms, the medication contributes to improved comfort and assists with maintaining functional stability during periods of heightened discomfort.

Quick Fact: Relief for Dual Skin Distress
Therapeutic Focus Symptomatic support for inflammatory conditions with microbial involvement.
Symptoms Addressed Redness (erythema), swelling, itching, crusting, and weeping.
Clinical Scenarios Acute flare-ups of chronic eczema complicated by bacterial infection.

Eligibility and Restrictions for Use

Who Can and Cannot Use Fudic-BNF?

Eligibility for Fudic-BNF is determined by the patient's age and the specific nature of their skin condition, as documented in official regulatory labeling.

Contraindicated Populations and Conditions

Fudic-BNF is contraindicated and must not be used by individuals with the following:

  • Hypersensitivity to fusidic acid, beclometasone dipropionate, or any of the product's inactive ingredients.
  • Primary skin infections caused by viruses (e.g., Herpes simplex, Varicella), fungi (systemic or local), or those related to tuberculosis or syphilis.
  • Specific non-infectious skin conditions such as Rosacea, Perioral Dermatitis, and rashes that follow a vaccination.

Age-Related and Conditional Eligibility

Population Category Official Eligibility Status Regulatory Requirement
Infants Contraindicated Must not be used in children under one year of age.
Children Restricted Use Use requires caution due to a greater risk of systemic side effects from the corticosteroid component. Treatment must be limited in duration and amount.
Pregnancy Conditional Use Not recommended unless use is clearly necessary, as safety in human pregnancy is not fully established.
Lactation Permitted with Restriction Can be used during breastfeeding, but the cream must not be applied to the breast to prevent accidental ingestion by the infant.

Eligibility for use in children, pregnant, and breastfeeding individuals is granted under specific restrictions to mitigate risks documented by regulatory authorities. Conversely, the official contraindications establish absolute exclusions, primarily due to the risk of the corticosteroid component masking or exacerbating the excluded conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Fudic-BNF acknowledges that formal drug interaction studies have not been performed for the topical combination. The likelihood of systemic interactions is deemed minimal due to the negligible systemic absorption of both active components under correct topical use.

However, the profile includes critical interaction cautions based on the systemic properties of the Fusidic Acid component. Treatment with HMG-CoA reductase inhibitors (Statins) is formally contraindicated with systemic Fusidic Acid due to the risk of rhabdomyolysis; this remains a principal caution if systemic absorption is high. Other documented systemic interactions concern exposure modification: co-administration with Oral Anticoagulants (Coumarin derivatives) may alter the anticoagulant effect, and use with certain HIV Protease Inhibitors may cause increased plasma concentrations of both agents, with a risk of hepatotoxicity.

Regarding local use, the official documentation describes important pharmacodynamic constraints. The co-application of other topical corticosteroids may lead to an additive effect, increasing the overall risk of systemic corticosteroid-related effects. Similarly, combining with other topical antibiotics may increase the documented risk of developing antibiotic resistance or contact sensitisation. Regulatory information notes a population-specific consideration for patients with hepatic impairment, as altered clearance of the Fusidic Acid component is possible if significant systemic absorption occurs. No interactions with food, alcohol, herbal products, or supplements are formally documented.

Mechanism of Action

Primary Molecular Target and Enzymatic Action

Fudic-BNF acts by binding to the Vitamin K Epoxide Reductase Complex 1 (VKORC1), which is essential for the activation of Vitamin K-dependent proteins. The drug facilitates the enzymatic modification of uncarboxylated osteocalcin (ucOC) to gamma-carboxyglutamic acid-containing osteocalcin (Gla-OC).

Pathway Modulation and Bone Matrix Integration

This modulation of osteocalcin function directly influences osteoblastic activity and the rate of calcium deposition. By regulating the substrate pool for hydroxyapatite crystal formation, the ultimate biochemical consequence is a shift in the local tissue environment. This shift favors the integration of mineral components into the bone matrix.

Regulation of Bone Turnover Equilibrium

This process regulates the dynamic equilibrium between osteoclast-mediated bone resorption and osteoblast-mediated bone formation at the cellular level.

Dosage and Administration Information

How to Use Fudic-BNF

Fudic-BNF is a fixed-dose combination product intended solely for topical administration to the skin. The usage of this medicine is structured around strict principles concerning its route, frequency, quantity, and duration, as outlined in official regulatory documentation.

Official Administration Guidelines

Feature Official Instruction and Principle
Route of Administration Topical (external use) only. The preparation must not be applied to the eyes or internal mucosal areas.
Dosing Schedule Apply a small amount sufficient to cover the affected area in a thin film.
Frequency Pattern Typically applied twice daily (e.g., morning and evening).
Duration of Course Treatment is for short-term use and should not normally exceed 14 days (two weeks).

Procedural and Population Rules

Before application, users are generally instructed to wash hands thoroughly, unless the hands are the area requiring treatment. If a dose is missed, it should be applied when remembered; however, a double amount must not be used to compensate.

Use in pediatric patients must be approached with caution. Official instructions specify that application under occlusion, use of large amounts, or prolonged treatment in children and infants must be avoided to limit the risk of increased systemic absorption of the corticosteroid component. Furthermore, the use of occlusive dressings is generally not recommended for any patient unless specifically directed by a healthcare professional.

Recent Clinical Evidence

Fudic-BNF: Recent Clinical Evidence

Research has been studied regarding outcomes in acute, uncomplicated diarrhea. Fudic-BNF is a naturally occurring compound that has been the focus of various trials across multiple continents. The following summarizes key findings from studies evaluating the compound.

Research into the Compound's Action

Research explored the compound's influence on the gut barrier. An associated hypothesis is the potential influence on fluid loss. Research has examined the compound's effect profile in relation to the severity of acute diarrhea.

Clinical Trial Findings

Study Outcomes in Acute Diarrhea

Large-scale, randomized controlled trials (RCTs) have been the primary method for gathering data. One large-scale trial reported that participants who received the compound for seven days had a difference in the number of bowel movements compared to the placebo group. The trial further indicated a potential association with the overall duration of the diarrheal episode. This finding is part of the evidence base regarding the compound for acute gastrointestinal issues.

Formulation Studies

Other studies focused on the delivery method. They found that this formulation showed a difference in the observed time to relief of symptoms compared to the traditional delivery methods evaluated in the study.

Dosing Parameters and Safety Profile Studied

Studies have primarily evaluated the compound in adults. The research focused on specific dose ranges and administration periods. Doses higher than the amount used in the trials were not evaluated. Side effect findings in the research reviewed were reported to be similar to those of the placebo group, with gastrointestinal discomfort being the most frequent reported adverse event.

Frequently Asked Questions (FAQ)

Common questions about Fudic-BNF (FAQ)

Q: How quickly does Fudic-BNF usually start to work?

Regulatory information does not provide an exact timeframe for symptom relief. However, the potent corticosteroid component, Beclometasone, is generally known for rapid anti-inflammatory effects. The rapid anti-inflammatory effects of the corticosteroid component may be associated with a potential reduction in symptoms like itching and redness within a few days, though individual responses can vary.

Q: Is Fudic-BNF available over the counter?

The official product classification, according to regulatory sources like the British National Formulary (BNF) and government guides, shows that Fudic-BNF is typically classified as a Prescription Only Medicine (POM). Due to its potent corticosteroid and antibiotic components, it is not typically available for purchase over the counter.

Q: Are there any known interactions between Fudic-BNF and common pain relievers?

Since Fudic-BNF is applied topically, the risk of interactions with orally taken medicines, like pain relievers, is low. However, official systemic data for the antibiotic component, Fusidic Acid, shows that its metabolism can sometimes be affected by other drugs, including a common pain reliever like Acetaminophen (Paracetamol). This is a general caution and mainly relevant if significant amounts of the topical drug are absorbed into the body.

Q: Can Fudic-BNF affect blood sugar levels?

If the corticosteroid component (Beclometasone) is absorbed into the bloodstream in large amounts—usually through widespread, prolonged use or use under airtight dressings—it may cause hormonal imbalances. These hormonal changes (such as adrenal suppression or Cushing's syndrome) are recognized to potentially be associated with changes in blood sugar levels. Official warnings highlight that this is a risk to monitor, particularly when using the medicine outside of the recommended guidelines.

Q: What is the consistency of Fudic-BNF cream/ointment?

Fudic-BNF is supplied in two different forms. The cream version is generally white and water-based, while the ointment version is typically described as a more greasy, oil-based preparation. The difference in forms allows for selection based on the specific characteristics of the skin area being treated.

Q: Is Fudic-BNF used for burns or minor cuts?

The medicine is indicated for inflammatory skin conditions with potential bacterial involvement. Regulatory cautions advise against application to open wounds, broken skin, or lesions, which may increase the risk of systemic absorption. The official use is for conditions like infected eczema.

Q: Does Fudic-BNF have any effect on blood pressure?

Regulatory sources do not list high or low blood pressure as a common or uncommon side effect of this topical medication. While significant systemic absorption of the corticosteroid component can influence overall body processes, official regulatory documents do not list changes in blood pressure as a common or uncommon side effect for the topical application.

Q: Is Fudic-BNF a common prescription for dermatitis?

Official documents indicate that Fudic-BNF is officially prescribed for the management of infected eczema and dermatitis where a bacterial infection is either present or suspected. The dual action of the steroid and the antibiotic is designed for these types of conditions.

Q: Is Fudic-BNF known to cause changes in skin color?

Official product information, including summaries of undesirable effects, lists skin discoloration or pigmentation changes as an adverse reaction. This effect is generally associated with the topical application of potent corticosteroids like Beclometasone, one of the active ingredients in Fudic-BNF.

Q: Are there special considerations for using Fudic-BNF on older patients?

While there are no specific contraindications solely for older patients, the general risk warnings regarding the corticosteroid component still apply. Older patients may be at a greater potential risk for certain side effects like skin thinning. Regulatory information indicates that use in this population requires the awareness of potential increased sensitivity to systemic effects.

Q: How does Fudic-BNF compare to over-the-counter hydrocortisone?

Fudic-BNF contains Beclometasone Dipropionate, which is officially classified as a potent topical corticosteroid. This contrasts with over-the-counter hydrocortisone, which is generally classified as a mild or low-potency corticosteroid. This difference in potency aligns with Fudic-BNF's status as a Prescription Only Medicine.

Q: What are the signs that Fudic-BNF is not working?

According to regulatory guidance, treatment should be re-evaluated if the skin condition worsens (e.g., increased redness or swelling) or if there is no improvement after the recommended short treatment course (typically 14 days). If the symptoms persist or deteriorate, this warrants consultation with a healthcare professional.

Q: Why is it recommended to wash hands after using Fudic-BNF?

Official administration instructions detail that washing hands after application helps prevent the accidental transfer of the medicine. This stops the drug from reaching sensitive areas like the eyes or internal mucous membranes, or from being inadvertently spread to other people.

Q: Can I use Fudic-BNF if I have a known allergy to other corticosteroids?

The official product information primarily contraindicates use if there is a known hypersensitivity to the specific components: Fusidic Acid or Beclometasone Dipropionate. Although not explicitly stated, patients with a known allergy to one class of corticosteroid may experience cross-reactivity. This circumstance suggests the need for review against the official product label.

Q: Can I mix Fudic-BNF with another topical product?

Regulatory sources caution against using Fudic-BNF at the same time as other topical corticosteroids or other topical antibiotics to avoid the potential for additive effects or for issues related to antibiotic resistance. Using non-medicated topical products (like lotions or cleansers) is not strictly forbidden, but official documents do not provide procedural guidance for mixing or sequential application.

Q: Can Fudic-BNF be used on broken skin?

Cautions from regulatory bodies advise that application to open wounds or severely broken skin should be avoided. Applying the medicine to damaged skin can increase the amount of corticosteroid that is absorbed into the body, which is associated with a greater potential risk of systemic side effects.

How should Fudic-BNF be stored and disposed of?

How to Store and Dispose of Fudic-BNF

Storage Requirements

Fudic-BNF Cream must be stored at a temperature not exceeding 25°C or 30°C, as specified on the product label, and kept in a cool and dry place. The medicine requires protection from direct sunlight and heat. To maintain the stability of the cream, the tube must be kept tightly closed when not in use.

Storage Restriction Requirement
Temperature Store below 25 C / 30 C (check label).
Protection Protect from heat and direct sunlight.
Safety Keep out of the sight and reach of children.

Disposal and Stability

Do not use the cream past the expiry date. Furthermore, regulatory guidelines advise that the product be discarded after a defined period following the initial opening, such as 28 days. Unused or expired Fudic-BNF must not be disposed of in household waste or wastewater. Patients should consult a pharmacist for instructions on how to properly discard the medicine using an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fudic-BNF found in:

A-Z Index: